Syngene International

OverviewSuggest Edit

Syngene International is integrated research, development, and manufacturing company providing scientific services. It conducts early-stage research, pre-clinical and clinical trials, drug substance and drug product development, biologics manufacturing, and other services. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical industries.

TypePublic
Founded1993
HQBangalore, IN
Websitesyngeneintl.com
Employee Ratings3.6
Overall CultureC

Latest Updates

Employees (est.) (Apr 2022)5,437
Revenue (FY, 2022)₹25.1 B(+20%)
Share Price (Aug 2022)₹563.8(-1%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Syngene International

Jonathan Hunt

Jonathan Hunt

Managing Director and Chief Executive Officer
Mahesh Bhalgat

Mahesh Bhalgat

Chief Operating Officer
Alok Mehrotra

Alok Mehrotra

Chief Quality Officer
Kenneth Barr

Kenneth Barr

Senior Vice President – Discovery Services
Sanjeev Sukumaran

Sanjeev Sukumaran

Chief Human Resources Officer
Catherine Rosenberg

Catherine Rosenberg

Non-Executive Director
Show more

Syngene International Office Locations

Syngene International has offices in Bangalore and Bengaluru
Bangalore, IN (HQ)
Bommasandra Industrial Area – Phase-IV, Jigani Link Road
Bangalore, IN
No.39 A, Near Semicon Park, Electronic city, Phase II Hosur Road
Bengaluru, IN
No.39 A, Hosur Rd, near Semicon Park, Electronic City Phase II, Electronic City
Show all (3)

Syngene International Financials and Metrics

Syngene International Revenue

Embed Graph
View revenue for all periods
Syngene International's revenue was reported to be ₹25.07 b in FY, 2022
INR

Revenue (Q1, 2023)

6.4b

Gross profit (Q1, 2023)

5.0b

Gross profit margin (Q1, 2023), %

77.4%

Net income (Q1, 2023)

739.0m

EBITDA (Q1, 2023)

1.9b

EBIT (Q1, 2023)

1.1b

Market capitalization (2-Aug-2022)

222.8b

Closing stock price (2-Aug-2022)

563.8

EV

222.8b
Syngene International's current market capitalization is ₹222.8 b.
Annual
INRFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022

Revenue

13.2b17.2b18.8b20.9b25.1b

Cost of goods sold

(3.8b)(5.3b)(5.2b)(5.3b)(7.5b)

Gross profit

10.4b12.9b14.9b16.5b18.5b

Gross profit Margin, %

79%75%79%79%74%
Quarterly
INRQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022Q1, 2023

Revenue

4.1b4.2b4.7b4.2b4.6b5.2b4.2b5.2b5.8b5.9b1.2b6.4b6.4b

Cost of goods sold

(1.3b)(1.1b)(1.4b)(1.1b)(1.3b)(1.4b)(897.0m)(1.3b)(1.5b)(1.9b)(362.1m)(1.7b)(1.6b)

Gross profit

3.0b3.3b3.4b3.4b3.6b3.9b3.5b4.1b4.5b4.1b867.8m4.8b5.0b

Gross profit Margin, %

73%78%73%80%78%76%82%78%78%69%72%75%77%
Annual
INRFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022

Cash

9.7b4.4b2.8b6.4b5.2b

Accounts Receivable

2.7b3.4b4.0b3.4b5.1b

Prepaid Expenses

95.0m248.0m253.0m299.0m606.0m

Inventories

860.0m434.0m252.0m596.0m1.8b
Quarterly
INRQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022Q1, 2023

Cash

5.4b2.4b7.1b335.7m

Accounts Receivable

2.7b2.9b2.7b357.3m

Inventories

730.0m511.0m582.0m165.5m
Annual
INRFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022

Net Income

3.1b3.3b4.1b4.0b4.0b

Depreciation and Amortization

1.3b1.6b2.1b2.6b2.9b

Inventories

(538.0m)426.0m182.0m(344.0m)(1.2b)

Accounts Payable

1.2b
Quarterly
INRQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022Q1, 2023

Net Income

2.0b1.4b144.0m

Depreciation and Amortization

1.0b1.3b150.9m

Inventories

(77.0m)(330.0m)(105.9m)
INRFY, 2018

Revenue/Employee

3.2m

Debt/Equity

0.5 x

Debt/Assets

0.3 x

Financial Leverage

1.9 x
Show all financial metrics

Syngene International Operating Metrics

FY, 2018FY, 2019FY, 2020

Active Clients

316331360

Engineers And Scientists

3.54 k4 k4.2 k

Patents Issued

400400

Syngene International Acquisitions / Subsidiaries

Company NameDateDeal Size
Strand Life Sciences - BioinformaticsOctober 20, 2016
Syngene USA Inc

Syngene International Revenue Breakdown

Embed Graph

Syngene International revenue breakdown by business segment: 100.0% from CONTRACT RESEARCH AND MANUFACTURING SERVICES.

Syngene International revenue breakdown by geographic segment: 10.7% from INDIA, 17.2% from REST OF WORLD and 72.1% from UNITED STATES OF AMERICA

Syngene International Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Syngene International Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Syngene International Online and Social Media Presence

Embed Graph

Syngene International Company Culture

  • Overall Culture

    C

    66/100

  • CEO Rating

    B

    70/100

  • Compensation

    D

    51/100

Learn more on Comparably

Syngene International News and Updates

Syngene International Q1 Review - Order Win Vindicates Capabilities; Execution To Be The Key: ICICI Direct

Syngene International Q1 Review - Order Win Vindicates Capabilities; Execution To Be The Key: ICICI Direct

Syngene International, Zoetis To Manufacture Drug Treating Osteoarthritis In Dogs

Syngene International signed a 10-year agreement with animal health company Zoetis to manufacture the drug substance for Librela which is used for treating osteoarthritis in dogs.

Syngene International Q1 Review - Mixed Numbers; Remdesivir Impacts Margins: ICICI Direct

Syngene International Q1 Review - Mixed Numbers; Remdesivir Impacts Margins: ICICI Direct

Syngene International consolidated net profit rises 33.28% in the June 2021 quarter

Net profit of Syngene International rose 33.28% to Rs 77.30 crore in the quarter ended June 2021 as against Rs 58.00 crore during the previous quarter ended June 2020.

Syngene International appoints Kush Parmar as an Additional Director

Syngene International said in the regulatory filing on Tuesday that it has appointed Dr. Kush Parmar as an Additional Director (Independent, Non-Executive), for a tenure commencing from today (i.e. the date of allotment of DIN) till the conclusion of the 31st Annual General Meeting of the Company pr…

Syngene International appoints Sanjeev Sukumaran as CHRO

Syngene International has appointed Sanjeev Sukumaran as Chief Human Resource Officer (CHRO) with effect from June 1, 2021. Sukumaran succeeds Vinita Shrivastava.
Show more

Syngene International Blogs

Analytical Development Services – IND Filing to Commercialization

Syngene has one of the largest Analytical facilities in Asia. The facility supports small and large molecules programs from early development to CMC filing and commercialization.

Minimizing environmental footprint the Syngene way

How Syngene is driving behavioural change in responsible use of natural resources while researching new technology and opportunities to improve its sustainability performance continuously.

Syngene Discovery Services

Syngene’s end-to-end Drug Discovery platform allows us to offer integrated and standalone services from Target Identification to IND enabling.

Enabling early assessment of drug targets to maximize clinical and commercial success

Comprehensive diligence around a target at the start of a discovery program can make the difference between success and failure. Learn how Syngene’s Target Assessment service enables informed decision-making resulting in increased clinical and commercial success.

Integrated or Standalone: How the industry thinks about drug development outsourcing

Read this white paper to gain insights about perceptions around integrated and standalone outsourcing. The white paper is based on surveys conducted across emerging biopharma, mid-size and large pharma in North America, Europe and other regions.

Essential In vivo Safety – Tox studies to move your molecule from Target to IND successfully

Learn about Syngene’s expertise in  Safety/Tox studies that allows us to guide you through the various requirements leading to successful IND submission.
Show more

Syngene International Frequently Asked Questions

  • When was Syngene International founded?

    Syngene International was founded in 1993.

  • Who are Syngene International key executives?

    Syngene International's key executives are Jonathan Hunt, Mahesh Bhalgat and Alok Mehrotra.

  • How many employees does Syngene International have?

    Syngene International has 5,437 employees.

  • What is Syngene International revenue?

    Latest Syngene International annual revenue is ₹25.1 b.

  • What is Syngene International revenue per employee?

    Latest Syngene International revenue per employee is ₹4.6 m.

  • Who are Syngene International competitors?

    Competitors of Syngene International include Mankind Pharma, NATCO Pharma and Cadila Pharmaceuticals.

  • Where is Syngene International headquarters?

    Syngene International headquarters is located at Bommasandra Industrial Area – Phase-IV, Jigani Link Road, Bangalore.

  • Where are Syngene International offices?

    Syngene International has offices in Bangalore and Bengaluru.

  • How many offices does Syngene International have?

    Syngene International has 3 offices.